{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000048","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.208081+00:00","generated_at":"2026-05-18T19:10:20.786886+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vistagen appoints Elissa Cote as Chief Corporate Development Officer","bullets":["Cote appointed CCDO effective June 23, 2025, to lead strategic partnerships and pherine platform advancement.","Nearly 30 years biopharma BD experience; previously Chief Strategy/BD Officer at Mallinckrodt Pharmaceuticals.","Received inducement option for 150,000 shares at June 23 closing price; vests 25% year one, then monthly over 36 months.","Pipeline includes five intranasal pherine candidates targeting six CNS disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000048","json":"https://secwatch.observer/filing/0001411685-25-000048.json","markdown":"https://secwatch.observer/filing/0001411685-25-000048.md","text":"https://secwatch.observer/filing/0001411685-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000048/0001411685-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000048/vtgn-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:10:20.786886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}